Anti-CD20 monoclonal antibodies: historical and future perspectives

被引：182

作者：

Lim, Sean H. ^{[1
]}

Beers, Stephen A. ^{[1
]}

French, Ruth R. ^{[1
]}

Johnson, Peter W. M. ^{[1
]}

Glennie, Martin J. ^{[1
]}

Cragg, Mark S. ^{[1
]}

机构：

[1] Univ Southampton, Sch Med, Tenovus Lab, Gen Hosp,Canc Sci Div, Southampton SO16 6YD, Hants, England

来源：

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2010年 / 95卷 / 01期

关键词：

CD20; monoclonal antibodies; lymphoma; immunotherapy; NON-HODGKINS-LYMPHOMA; B-CELL LYMPHOMA; CHRONIC LYMPHOCYTIC-LEUKEMIA; FC-GAMMA-RIIIA; CHEMOTHERAPY PLUS RITUXIMAB; FRESH-FROZEN PLASMA; FOLLICULAR LYMPHOMA; IN-VIVO; LOW-GRADE; PHASE-I/II;

D O I：

10.3324/haematol.2008.001628

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Antibodies to CD20 have confirmed the hypothesis that monoclonal reagents can be given in vivo to alleviate human diseases. The targeting of CD20 on normal, malignant and auto-immune B-lymphocytes by rituximab has demonstrated substantial benefits for patients with a variety of B-cell lymphomas, as well as some with autoimmune disorders. There has been a notable increase in the survival rates from B-cell lymphoma in the decade since anti-CD20 therapy was introduced.

引用

页码：135 / 143

页数：9

共 114 条

[1] Alas S, 2001, CANCER RES, V61, P5137
[2] Alas S, 2001, CLIN CANCER RES, V7, P709
[3] Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: Relationship to in vivo rituximab resistance
Bannerji, R
Kitada, S
Flinn, IW
Pearson, M
Young, D
Reed, JC
Byrd, JC
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (08) : 1466 - 1471
[4] Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation
Beers, Stephen A.
Chan, Claude H. T.
James, Sonya
French, Ruth R.
Attfield, Kathrine E.
Brennan, Claire M.
Ahuja, Anupama
Shlomchik, Mark J.
Cragg, Mark S.
Glennie, Martin J.
[J]. BLOOD, 2008, 112 (10) : 4170 - 4177
[5] The shaving reaction: Rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes
Beum, PV
Kennedy, AD
Williams, ME
Lindorfer, MA
Taylor, RP
[J]. JOURNAL OF IMMUNOLOGY, 2006, 176 (04) : 2600 - 2609
[6] Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab
Bowles, Julie A.
Wang, Siao-Yi
Link, Brian K.
Allan, Barrett
Beuerlein, Gregory
Campbell, Mary-Ann
Marquis, David
Ondek, Brian
Wooldridge, James E.
Smith, Brian J.
Breitmeyer, James B.
Weiner, George J.
[J]. BLOOD, 2006, 108 (08) : 2648 - 2654
[7] Pharmacokinetic and Pharmacodynamic Properties of TRU-015, a CD20-Directed Small Modular Immunopharmaceutical Protein Therapeutic, in Patients with Rheumatoid Arthritis: A Phase I, Open-Label, Dose-Escalation Clinical Study
Burge, Daniel J.
Bookbinder, Stephen A.
Kivitz, Alan J.
Fleischmann, Roy M.
Shu, Cathye
Bannink, Jeannette
[J]. CLINICAL THERAPEUTICS, 2008, 30 (10) : 1806 - 1816
[8] The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction
Byrd, JC
Kitada, S
Flinn, IW
Aron, JL
Pearson, M
Lucas, N
Reed, JC
[J]. BLOOD, 2002, 99 (03) : 1038 - 1043
[9] Neutrophil role in in vivo anti-lymphoma activity of rituximab:: FCGR3B-NA1/NA2 polymorphism does not influence response and survival after rituximab treatment
Cartron, G.
Ohresser, M.
Salles, G.
Solal-Celigny, P.
Colombat, P.
Watier, H.
[J]. ANNALS OF ONCOLOGY, 2008, 19 (08) : 1485 - 1487
[10] From the bench to the bedside: ways to improve rituximab efficacy
Cartron, G
Watier, H
Golay, J
Solal-Celigny, P
[J]. BLOOD, 2004, 104 (09) : 2635 - 2642

← 1 2 3 4 5 6 7 8 9 10 →